Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V114 in Healthy Adults and Infants
NCT02531373Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2015
- Primary completion
- Apr 2017
- Modality
- Split/Subunit Vaccines
01
Overview
A Phase 2 trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Sep 2015; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02531373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531373.